Hydrogel Microneedles Loaded With a Reactive Oxygen Species-Responsive Carbon Monoxide Donor and Finasteride for Synergistic Treatment of Androgenetic Alopecia

This study developed a bifunctional sodium hyaluronate microneedle patch incorporating glycyrrhizin-loaded dutasteride micelles and mesoporous polydopamine nanoparticles, which effectively inhibited DHT and reduced ROS in hair follicle cells, resulting in significantly accelerated hair growth in vitro and in vivo.

This study found that a microneedle system delivering VEGF and Ritlecitinib improved hair regeneration in mice with androgenetic alopecia, showing faster anagen onset and better hair quality compared to minoxidil.

This review discusses the criteria for evaluating treatments for androgenetic alopecia and emphasizes the importance of shared decision-making, noting no treatment currently meets all desired criteria of efficacy, safety, affordability, and ease of use.

This review highlights various plant-based and herbal treatments that reportedly help prevent hair loss and encourage hair growth. It also explores the molecular mechanisms, identified plant compounds, recent technologies such as nanoarchitectonics, and patents related to hair growth promotion.

This review discusses transdermal drug delivery using hydrogel-forming microneedles and highlights their potential for disease treatment, but notes challenges in their clinical application.

In this study, a microneedle patch containing conditioned media from hypoxia-pretreated stem cells enhanced hair regeneration in an androgenetic alopecia mouse model by boosting perifollicular vascularization and hair follicle stem cell activation compared to minoxidil.

This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.

This study found that a ceria nanozyme-integrated microneedles patch accelerated hair regeneration in an androgenetic alopecia mouse model more effectively than minoxidil, with reduced application frequency and minimal skin damage.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This study found that dihydrotestosterone induced hair loss and changes in hair morphology in male C57BL/6 mice, effects that could be partially reversed by the AR antagonist bicalutamide.

This letter discusses adverse events related to low-dose oral minoxidil for alopecia, highlighting age-related risks and stressing the importance of contraindication awareness with no new clinical results presented.

In this study, microneedles combined with finasteride nanostructured lipid carriers (FIN-NLC-MNs) were found to enhance skin penetration and specifically target hair follicles, promoting hair growth and gene regulation in androgenetic alopecia.

This review indicates that most studies reported positive effects of platelet-rich plasma injections for treating androgenic alopecia, with no major side effects, suggesting it may be a safe alternative to Minoxidil and Finasteride.

This review discusses potential biomarkers for alopecia and their significance, and while it highlights areas for future research, it reports no new clinical results.

In this study, researchers developed a new self-administered finasteride delivery system using powder-carrying microneedles that improved hair growth efficacy and addressed safety concerns compared to topical finasteride gel by allowing sustained intradermal release of the drug for three days with a single application.

This review discusses emerging targets for developing drugs to treat hair loss and reports no new clinical results; the authors emphasize the potential for therapies that regenerate hair follicles.

This study concluded that CD36-expressing dermal sheath cells may influence the modulation of blood capillaries in hair follicles, potentially affecting hair cycling.

This study found that finasteride-loaded microspheres effectively treated androgenic alopecia in a mouse model, showing similar hair growth effects to orally-administered finasteride.

This study found that in vivo, a novel microneedle system for valproic acid delivery may improve hair regrowth efficacy by upregulating hair follicle development pathways more effectively than topical application.

This study observed that the genes WNT7A, CASP7, and TNF were overexpressed in early stages of androgenetic alopecia, suggesting involvement of the WNT pathway, apoptosis, and inflammation in the disorder's development.

This review highlights that microneedling shows some promise for improving hair growth in alopecia, particularly when used with other treatments, though more research is needed to establish its efficacy and protocols.

This review discusses the potential benefits of activating NRF2 for treating hair follicle disorders linked to oxidative stress and reports no new clinical results.

This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.

This study observed that autologous platelet-rich plasma treatment improved hair count and density in areas with androgenetic alopecia compared to placebo, with differing outcomes based on the PRP collection device used.

This study found that DKK1 and WNT10b are paracrine factors that modulate hair follicle stem cell differentiation inhibition, contributing to androgenetic alopecia by affecting Wnt signaling in androgen-sensitive dermal papilla cells after dihydrotestosterone stimulation.

This study found that activating Nrf2 in human hair follicles significantly reduced oxidative stress, lipid peroxidation, and protected against hair growth inhibition, suggesting a protective role for Nrf2 against redox insult in this context.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

This study suggests that down-regulation of vasculature-related genes in dermal papilla cells from balding scalps might contribute to the development of androgenetic alopecia.

This study found that freeze-dried finasteride nanoparticles improved the stability, solubility, and in vitro dissolution of the drug, indicating potential benefits for poorly water-soluble drugs.

This study suggests that oxidative stress may contribute to androgenetic alopecia by inducing premature senescence and secretion of hair growth inhibitors in dermal papilla cells from balding scalp.

This review discusses the development of an algorithmic guideline for treating androgenetic alopecia in Asian patients, using the BASP classification to address limitations of previous guidelines, and reports no clinical results.

This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This study found that VEGF significantly enhances perifollicular vascularization during the hair growth phase, accelerating hair regrowth and increasing follicle and hair size, while its inhibition retards hair growth.

Hair follicles in people with alopecia have lower levels of a key blood vessel growth protein.